submit to the journals
Liver Cancer: FEATURED VIDEOS
Conference Highlights
Leading the Debate on the Advances in Healthcare
Liver Cancer: FEATURED Articles
flipper_slider
Tumour Lysis Syndrome in Solid Tumours Associated with Tyrosine Kinase Inhibitors – A Case Illustrated Review
European Oncology & Haematology, 2016;12(1):51–4 DOI: https://doi.org/10.17925/EOH.2016.12.01.51
Cancer Stem Cells and Cancer Stem Cell Inhibitors in Gastrointestinal Cancers
Oncology & Hematology Review, 2016;12(1):41–6 DOI: http://doi.org/10.17925/OHR.2016.12.01.41
American Society of Clinical Oncology 2015— Highlights of Non-colorectal Gastrointestinal Cancers
Oncology & Hematology Review, 2015;11(2):137–8 DOI: http://doi.org/10.17925/OHR.2015.11.02.137
Making Sense of the Advances in the Treatment of Hepatocellular Carcinoma
Oncology & Hematology Review, 2015;11(2):141–2 DOI: http://doi.org/10.17925/OHR.2015.11.02.141
Editor's choice
Oncology & Hematology Review, 2016;12(1):41–6 DOI: http://doi.org/10.17925/OHR.2016.12.01.41
European Oncology & Haematology, 2016;12(1):51–4 DOI: https://doi.org/10.17925/EOH.2016.12.01.51
Liver Cancer: Latest Articles
European Oncology & Haematology, 2016;12(1):51–4 DOI: https://doi.org/10.17925/EOH.2016.12.01.51
European Oncology & Haematology, 2016;12(1):51–4 DOI: http://doi.org/10.17925/EOH.2016.12.01.51
Oncology & Hematology Review, 2016;12(1):41–6 DOI: http://doi.org/10.17925/OHR.2016.12.01.41
Oncology & Hematology Review, 2015;11(2):141–2 DOI: http://doi.org/10.17925/OHR.2015.11.02.141
Oncology & Hematology Review, 2015;11(2):137–8 DOI: http://doi.org/10.17925/OHR.2015.11.02.137
Oncology & Hematology Review, 2012;8(1):43–7 DOI: http://doi.org/10.17925/OHR.2012.08.1.43
Liver Cancer: FEATURED VIDEOS
Editor's choice
Jeff Evans, of the University of Glasgow, UK, talks to us about the advances in the clinical development of lenvatinib and its potential use in combination with pembrolizumab for the treatment of hepatocellular carcinoma.
1. What is the latest progress on the clinical development of lenvatinib for the treatment of unresectable hepatocellular carcinoma both in monotherapy and in combination with pembrolizumab? And what is the latest data on lenvatinib in hepatocellular carcinoma at ASCO? (0:11)
2. What is the significance of lenvatinib as a monotherapy for patients with hepatocellular carcinoma? (1:02)
3. What is the rationale for combined therapy with lenvatinib and pembrolizumab? (1:36)
4. Which patients are most likely to benefit from this approach and in what stage of their treatment pathway? (2:04)
5. What in your opinion is the potential for lenvatinib for patients with hepatocellular carcinoma or indeed other tumour patients? (2:29)
Speaker disclosures: Jeff Evans has provided consultancy services to Eisai, Bristol-Myers Squibb, Celgene, Bayer and Karus Therapeutics.
Filmed at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018, Chicago, IL, US, June 1–5 2018
Based on the results of the phase I part of the study, eight (19%) of the 42 evaluable patients responded to the anti-PD-1 antibody with tumour reduction beyond 30%. More importantly, the responses have been durable and surpassed 12 months in four patients. The overall survival rate at 12 months was 62%.
Liver Cancer: Latest Videos
Video List based on Category on Node Page
Latest Videos
Jeff Evans, of the University of Glasgow, UK, talks to us about the advances in the clinical development of lenvatinib and its potential use in combination with pembrolizumab for the treatment of hepatocellular carcinoma.
1. What is the latest progress on the clinical development of...
Jeff Evans discusses the key findings from the phase III REFLECT study, and how these results might impact the future management of liver cancer patients.
Speaker disclosures: Consultancy for Eisai for Advisory Boards. Support for clinical trials (all payments to university).
Filmed at the...
Based on the results of the phase I part of the study, eight (19%) of the 42 evaluable patients responded to the anti-PD-1 antibody with tumour reduction beyond 30%. More importantly, the responses have been durable and surpassed 12 months in four patients. The overall survival rate at 12 months...
After local chemotherapy of the liver, the catheter filters out excess drug that is prevented from travelling to the rest of the body. This minimizes the potential for toxic side effects and may allow the use of higher local doses that increase treatment efficacy.
Sarah Cannon Radiation Oncology Physician-in-Chief Andrew Kennedy, M.D., discusses metastatic colorectal cancer and answers participants' questions during this CancerConnect Web Chat with the Experts titled, "Using Radiation to Treat Colorectal Cancers Metastasized to the Liver." During the web...
Palliative Care for patients with Liver Cancer
LATEST TWEETS
Out Now
Conference Highlights